Anbio Biotechnology Class A (NNNN)
NASDAQ: NNNNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NNNN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $145.72M
- P/E (TTM)
- 22.13
- EPS (TTM)
- $0.15
- Dividend yield
- None
- 52-week range
- 3.09 – 44.73
- Day range
- 3.31 – 3.93
- Volume / Avg
- 79.51K / 128.35K
- Beta
- —
- Shares outstanding
- 43.89M
52-week range
NNNN stock today
On Nov 20, NNNN ended the session at $3.32, shedding $0.33 (9.04%), versus the S&P 500's 3.70% decline. At this level, NNNN sits near the bottom of its 52-week range of $3.09 to $44.73: 92.6% below the high, set on Dec 5, 2025 and 7.4% above the low. NNNN is down 89.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.0%.
Anbio Biotechnology trades at 22.1x its trailing twelve-month earnings per share of $0.15.
Summary generated from market data by MetaCap's automated system. Methodology
About Anbio Biotechnology
Company profileAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Michael Lau M.B.A., Ph.D.
- Headquarters
- Frankfurt am Main
- Employees
- 27
- IPO year
- 2025
- Website
- anbiobiotechnology.com
Financial highlights
Full financialsIn fiscal 2025, Anbio Biotechnology generated $8.6 million in revenue, up 5.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.4 million (+169.9% year over year), for a net margin of 74.1% versus a median of 33.6% in the prior 3 years. Gross margin was 87.2% (up from 71.9%) and operating margin 66.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Growth | +5.64% | +21.95% | -71.49% | — |
| Net income | $6.40M | $2.37M | $2.25M | $10.01M |
| EPS (diluted) | $0.147 | $0.056 | $0.105 | $100,112.00 |
Anbio Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs NNNN |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs NNNN |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs NNNN |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs NNNN |
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs NNNN |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs NNNN |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs NNNN |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs NNNN |
Indexes, lists and sector
Anbio Biotechnology stock FAQ
What is Anbio Biotechnology's stock price today?
NNNN last traded at $3.32 as of Nov 20, 4:00 PM EST, down 9.04% on the day. Prices are delayed at least 15 minutes.
What is NNNN's P/E ratio?
NNNN trades at a trailing P/E ratio of 22.13.
Who is Anbio Biotechnology's CEO?
Mr. Michael Lau M.B.A., Ph.D. is the chief executive officer of Anbio Biotechnology Class A, which has about 27 employees.
What is the NNNN 52-week high?
The 52-week high for NNNN is $44.73 and the 52-week low is $3.09. The stock is currently 92.6% below its high.